Peer Reviewed Clinical Study for H3.1 Biomarker Published in Critical Care HENDERSON, Nev., June 12, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the publication of a new clinical manuscript suggesting that the Nu.Q® H3.1 biomarker has the potential to inform clinical care in critically-ill Intensive Care Unit (ICU) patients in the assessment of sepsis, organ failure and subphenotypes.Dr. Andrew Retter, Chief Medical Office ...

Castle Biosciences (CSTL) 2025 Conference June 04, 2025 07:35 AM ET Speaker0 Good morning. My name is Derek Maslow. I'm the CEO of Casa Biosciences. With me today is Frank Stokes, our CFO. I want to thank Jefferies Conference for the opportunity to come and present today and look forward to taking questions when we get done. Let's talk a little bit about Castle Biosciences. First, I encourage everybody to read through our disclaimers on the corporate presentation located on our website. So we try and focus ...

FRIENDSWOOD, Texas, May 09, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data from the first independent validation of the recently published Collaborative Ocular Oncology Group Study No. 2 (COOG2.1) by Harbour et al.1 The data, from a real-world cohort of 1,297 patients with uveal melanoma (UM), was presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Mee ...